IKNA News and Press, Ikena Oncology Inc. From 11/09/23

2023-11-09 10:00:37 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...

Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptions Encouraging signs of clinical activity and tumor shrinkage in multiple patients with...

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor confer...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Ikena Oncology Inc. (IKNA) is expected to report $-0.44 for Q3 2023

2023-09-22 14:28:36 ET More on Ikena Oncology Ikena falls on acquisition of Pionyr in all-stock deal Seeking Alpha’s Quant Rating on Ikena Oncology Historical earnings data for Ikena Oncology Financial information for Ikena Oncology ...

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor confere...

2023-08-21 11:52:45 ET More on Health Care Select Sector SPDR XLV Vs. VHT: A Head-To-Head Healthcare ETF Comparison XLV: The Powerhouse ETF Driving Health And Wealth BlackRock spotlights healthcare as an opportunity with recession talks in the air Goldman add...

2023-08-10 10:26:07 ET Ikena Oncology press release ( NASDAQ: IKNA ): Q2 GAAP EPS of -$0.44. Revenue of $2M. For further details see: Ikena Oncology GAAP EPS of -$0.44, revenue of $2M

Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational new drug (IND) submission planned by year end 2023 Underwritten public offering and acquisition of Pionyr add over $80M...